

What is it?

The Strategic Fund of the Pan American Health Organization is a regional mechanism for pooled procurement of essential medicines and strategic public health supplies for the countries of the Americas. The Fund pools demand from multiple countries and calls for international competitive bidding to procure quality-assured medicines and supplies at lower prices.

The purpose of the Strategic Fund is to improve access to quality, safe, and effective medicines and health supplies, while ensuring affordability and promoting efficient and sustainable health systems.



Who can use it?

All health ministries and government institutions providing public health services in Member States of the Pan American Health Organization/World Health Organization (PAHO/WHO) can procure medicines and supplies through the Strategic Fund after signing an agreement with the Organization.

Benefits of using the Strategic Fund



Quality, safety, and efficacy

Compliance with international standards on production and control.



Eligibility

WHO prequalification processes. Registration and commercialization in National Regulatory Authorities of Regional Reference.



Performance

Supplier performance evaluation.

What products are available for HIV, hepatitis B and C treatment?

The Strategic Fund list includes products for Human Immunodeficiency Virus (HIV) diagnosis and treatment, post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) for HIV infection, as well as treatment for viral hepatitis B and C and Sexually Transmitted Infections (STIs) for use in adult and pediatric populations, described in the following links:

- Strategic Fund products list: www.paho.org/strategicfund
- WHO list of prequalified diagnostic products: http://www.who.int/diagnostics_laboratory/evaluations/PQ_list/en/

New priority products recommended by WHO and reference prices*

FIRST-LINE ANTIRETROVIRALS (ARV) FOR HIV/AIDS

ARVs

- Tenofovir disoproxil fumarate (TDF) (300mg) + Lamivudine (3TC) (300mg) + Dolutegravir (DTG) (50mg)**: Bottle 30 TB

** The same combination of ARVs is recommended for PEP.

Reference price per bottle

USD 6.30

PREQUALIFIED MEDICINE FOR PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTION

ARVs

- Tenofovir disoproxil fumarate (TDF) (300mg) + Emtricitabine (FTC) (200mg): Bottle 30 TB

<http://www.who.int/hiv/topics/prep/en/>

Reference price per bottle

USD 4.75

PREQUALIFIED DIAGNOSTIC TESTS FOR HIV

- HIV RDT (Human immunodeficiency virus- Rapid diagnostic test)
- HIV RDT (Human immunodeficiency virus- Rapid diagnostic test) oral fluid***
- Rapid diagnostic tests (RDT) for HIV and syphilis
- Molecular tests for viral load and early diagnosis in exposed children (including cartridges for Xpert® HIV-1 Viral Load and Xpert® HIV-1 Qual Assay)

*** This product is available for HIV self-testing

MEDICATION RECOMMENDED BY WHO TO TREAT SYPHILIS****

- Benzathine benzylpenicillin vial 1.2 MIU
- Benzathine benzylpenicillin vial 2.4 MIU

**** The only treatment recommended by the WHO to prevent congenital syphilis in pregnant women

DIAGNOSTIC TESTS FOR STI

- Rapid Treponemal Tests for Syphilis
- HIV/Syphilis RDT Duo (Human immunodeficiency virus/Syphilis - Rapid diagnostic test)
- Molecular diagnostic tests for HPV (Care HPV test, Xpert®HPV)
- HCV Rapid molecular tests for the diagnosis for HCV Xpert®HCV

*Prices established in long-term agreements 2018-2021